AI Article Synopsis

  • Diabetic encephalopathy (DE) is linked to Alzheimer's disease and has been shown to impair learning and memory in animal studies, while neurotrophic peptides can improve these conditions.
  • APP 17-mer peptide offers neural protection but is prone to degradation; however, its modified version, P165, resists degradation and can be taken orally to protect neurons.
  • The study used high glucose and Aβ25-35 to damage human neuroblastoma cells and streptozotocin to induce diabetes in mice, finding that P165 positively influences synaptic and insulin signaling proteins, suggesting its potential as an Alzheimer's treatment.

Article Abstract

Diabetic encephalopathy (DE) is one of risk factors for Alzheimer's disease (AD). Our previous findings indicated that DE animals had impairment of learning and memory and degeneration of hippocampal neurons, which could be improved by neurotrophic peptide. APP 17-mer peptide is a synthesized peptide sequenced from soluble amyloid precursor protein. APP 17-mer peptide has neural protective effect, but is susceptible to enzyme degradation. Soluble APP 5-mer peptide is the active form of APP 17-mer peptide, and composed of arginine, glutamic acid, arginine, methionine and serine. P165, an APP 5-mer peptide analog reconstructed by our lab, is resistant to enzyme degradation, and can be orally used to protect neurons. In the present study, high glucose and Aβ25-35 were used to cause injury to human neuroblastoma cell line SH-SY5Y in vitro, and streptozotocin was used to induce diabetes in mice in vivo. The changes in synaptic proteins and proteins of insulin signal transduction which closely correlate with learning and memory were detected in these cells and the brain of mice. Results showed that P165 could up-regulate the expression of α-synuclein and insulin receptor (IR), down-regulate the expression of insulin receptor substrate-1 (IRS-1), PSD-95, Shank1 and MAPK expression. All these findings suggest that nicorandil might be a potential drug used for the treatment of AD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3992392PMC

Publication Analysis

Top Keywords

app 5-mer
12
5-mer peptide
12
app 17-mer
12
17-mer peptide
12
peptide
8
synaptic proteins
8
proteins insulin
8
insulin signal
8
signal transduction
8
learning memory
8

Similar Publications

Coronavirus Disease 2019 (COVID-19) is associated with increased incidence of neurological diseases and neuropsychiatric disorders after infection, but how it contributes to their development remains under investigation. Here, we investigate the possible relationship between COVID-19 and the development of ten neurological disorders and three neuropsychiatric disorders by exploring two pathological mechanisms: (i) dysregulation of host biological processes via virus-host protein-protein interactions (PPIs), and (ii) autoreactivity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) epitopes with host "self" proteins via molecular mimicry. We also identify potential genetic risk factors which in combination with SARS-CoV-2 infection might lead to disease development.

View Article and Find Full Text PDF
Article Synopsis
  • Diabetic encephalopathy (DE) is linked to Alzheimer's disease and has been shown to impair learning and memory in animal studies, while neurotrophic peptides can improve these conditions.
  • APP 17-mer peptide offers neural protection but is prone to degradation; however, its modified version, P165, resists degradation and can be taken orally to protect neurons.
  • The study used high glucose and Aβ25-35 to damage human neuroblastoma cells and streptozotocin to induce diabetes in mice, finding that P165 positively influences synaptic and insulin signaling proteins, suggesting its potential as an Alzheimer's treatment.
View Article and Find Full Text PDF

APP is required during an early phase of memory formation.

Eur J Neurosci

December 2000

Brain and Behaviour Research Group, The Open University, Milton Keynes, MK7 6AA, UK.

The amyloid beta/A4 protein precursor (APP) has been shown to be implicated in age-associated plastic changes at synapses that might contribute to memory loss in Alzheimer's disease. As APP has previously been reported to have multiple functions during normal development, we have employed a one-trial passive avoidance task in day-old chicks to study its role in the process of memory formation. Administration of anti-APP antibodies, injected 30 min pretraining, prevented memory for a one-trial passive avoidance task in day-old chicks without effects on general behaviour or initial acquisition.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!